Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 4 Results

Intervention Indication Therapeutic Area Year Actions
Cemiplimab as a monotherapy for advanced or metastatic non-small-cell lung cancer whose tumours express PD-L1 – first line Cemiplimab (Libtayo; REGN2810) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2020 View  |  Download
Cemiplimab for advanced cutaneous squamous cell Cemiplimab (Libtayo; REGN2810) Squamous cell carcinoma (SCC) Skin Cancer 2017 View  |  Download
Cemiplimab for recurrent, persistent or metastatic cervical cancer – second line Cemiplimab (Libtayo; REGN2810) Cervical cancer Female Reproductive Cancer 2020 View  |  Download
Cemiplimab in combination with chemotherapy for advanced or metastatic non-small cell lung cancer – first-line Cemiplimab (Libtayo; REGN2810) , Ipilimumab (Yervoy; BMS 734016; MDX 101) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2021 View  |  Download
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications